Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | MTOR | P42345 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6722530 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL720256 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL13908141 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL6722527 | 1.00 | PDE2A (0.50) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL10024088 | 0.89 | ADK (0.48) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL2584289 | 0.89 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL114751 | 0.89 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL114750 | 0.89 | LMNA (0.62) | LMNAMTORALDH1A1THRBMDM2 | |
| SCHEMBL10890263 | 0.88 | PDE2A (0.52) | PDE2AADORA3ADORA2AADORA1ADRA1A | |
| SCHEMBL10890255 | 0.88 | PDE2A (0.52) | PDE2AADORA3ADORA2AADORA1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416293-A1 | SYNTHESIS OF [18F]-LABELED THYMIDINE ANALOGUES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-12-28 | — | — | US | claimed |
| WO-2022109244-A1 | SYNTHESIS OF [18F] -LABELED THYMIDINE ANALOGUES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-05-27 | — | — | WO | claimed |
| US-8912319-B2 | Synthesis of 2′-deoxy-2′-[18F]fluoro-5-methyl-1-B-D-arabinofuranosyluracil (18F-FMAU) | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2014-12-16 | — | — | US | claimed |
| EP-0010205-B1 | 5-SUBSTITUTED 1-(2'-DEOXY-2'-SUBSTITUTED-BETA-D-ARABINOFURANOSYL) PYRIMIDINE NUCLEOSIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Sloan-Kettering Institute For Cancer Research (US) | 1983-05-04 | — | — | EP | claimed |
| US-4211773-A | VIRICIDES, ANTITUMOR AGENTS | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1980-07-08 | — | — | US | claimed |
| US-20230416293-A1 | SYNTHESIS OF [18F]-LABELED THYMIDINE ANALOGUES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2023-12-28 | — | — | US | disclosed |
| EP-2603516-B1 | SYNTHESIS OF 2'-DEOXY-2'-[18F]FLUORO-5-METHYL-1-B-D-ARABINOFURANOSYLURACIL (18F-FMAU) | UNIV SOUTHERN CALIFORNIA (US) | 2017-08-23 | — | — | EP | disclosed |
| US-8912319-B2 | Synthesis of 2′-deoxy-2′-[18F]fluoro-5-methyl-1-B-D-arabinofuranosyluracil (18F-FMAU) | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2014-12-16 | — | — | US | disclosed |
| EP-2603516-A2 | SYNTHESIS OF 2'-DEOXY-2'-[18F]FLUORO-5-METHYL-1-B-D-ARABINOFURANOSYLURACIL (18F-FMAU) | University of Southern California (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20120053337-A1 | SYNTHESIS OF 2'-Deoxy-2'-[18F]FLUORO-5-METHYL-1-B-D-ARABINOFURANOSYLURACIL (18F-FMAU) | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2012009666-A2 | SYNTHESIS OF 2'-DEOXY-2'-[18F]FLUORO-5-METHYL-1-B-D-ARABINOFURANOSYLURACIL (18F-FMAU) | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-01-19 | — | — | WO | disclosed |
| US-20040002476-A1 | Modified fluorinated nucleoside analogues | PHARMASSET, LTD. (BB) | 2004-01-01 | — | — | US | disclosed |
| US-4594339-A | Veterinary medicine | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1986-06-10 | — | — | US | disclosed |
| EP-0010205-B1 | 5-SUBSTITUTED 1-(2'-DEOXY-2'-SUBSTITUTED-BETA-D-ARABINOFURANOSYL) PYRIMIDINE NUCLEOSIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Sloan-Kettering Institute For Cancer Research (US) | 1983-05-04 | — | — | EP | disclosed |
| US-4211773-A | VIRICIDES, ANTITUMOR AGENTS | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1980-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416293-A1 | SYNTHESIS OF [18F]-LABELED THYMIDINE ANALOGUES | DCTD, DUT, RNMT | PDE2A 3437/4885ADORA3 1172/4885ADORA2A 470/4885 |
| US-20040002476-A1 | Modified fluorinated nucleoside analogues | SLC29A1, SLC29A2, SLC28A1 | PDE2A 1786/4885ADORA3 212/4885ADORA2A 187/4885 |
| US-20120053337-A1 | SYNTHESIS OF 2'-Deoxy-2'-[18F]FLUORO-5-METHYL-1-B-D-ARABINOFURANOSYLURACIL (18F-FMAU) | CGAS, RNGTT, ADA | PDE2A 51/4885ADORA3 433/4885ADORA2A 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.